Tenecteplase for medium vessel occlusion stroke (ARTS trial)
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests the clot-busting drug tenecteplase in people who had a stroke 4.5 to 24 hours ago due to a medium-sized artery blockage. It aims to see if this medication can improve outcomes without needing a procedure to remove the clot.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your stroke symptoms started between 4.5 and 24 hours ago (including wake-up strokes).
- A CT or MRI scan shows a blockage in a medium-sized brain artery (such as the M2, M3, A1–A3, or P1–P3 segments).
- You were independent before the stroke (able to do all usual activities).
- You do not plan to have a clot-removal procedure (endovascular therapy) and have not had recent major surgery or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called tenecteplase (a clot-buster) for people who have a moderate or severe stroke caused by a clot and can be treated 4.5 to 6 hours after symptoms start. It aims to see if this medicine can help improve recovery.
This trial tests a clot-busting drug called tenecteplase for people who had a stroke in the back of the brain and arrive at the hospital within 4.5 to 24 hours of symptoms. It aims to see if giving this drug later than usual can improve recovery and reduce disability.
This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.
This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the blocked blood vessel in the brain can help people with a medium-sized vessel occlusion stroke. The drug may help restore blood flow and reduce disability, and it is given within 24 hours of symptom onset.
This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.
Hear when a new Stroke, Ischemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.